Pub Date : 2025-09-09DOI: 10.1007/s11686-025-01127-7
Yan Zhao, Chao Zhang, Jing Zhang, Hui-Zhu Nan, Yue Xie, Lei Ma
Purpose
This study aimed to identify and analyze the role of Ferric reductase inBlastocystis sp. subtype 2 (ST2) and explore the relationship between the parasite and iron metabolism.
Methods
The location of Ferric reductase in Blastocystis sp. was determined using the indirect immunofluorescence assay (IFA). Transmission electron microscopy was employed to reveal the effect of iron ions on the cell membrane of Blastocystis sp.. For the first time, RNA interference technology was used to explore the relationship between Ferric reductase and iron ions.
Results
Ferric reductase was distributed in the membrane and cytoplasm of the parasite. Iron reduces the thickness of the Blastocystis sp.'s cell membrane. After silencing the Ferric reductase gene, there was no significant difference in the morphology of the parasite strain compared with the control group. The expression level of the Ferric reductase gene does not play a decisive role in maintaining the morphology of the parasite, but the deletion of the Ferric reductase gene reduces the ability of the parasite to absorb iron ions.
Conclusions
This study fills the gap in the research field of iron metabolism inBlastocystis sp. among parasites, lays a foundation for the research on the gene function of Blastocystis sp., and provides new candidate factors for the development of Blastocystis sp. vaccines.
{"title":"Ferric Reductase is a Key Factor in Regulating Iron Absorption by Blastocystis sp.","authors":"Yan Zhao, Chao Zhang, Jing Zhang, Hui-Zhu Nan, Yue Xie, Lei Ma","doi":"10.1007/s11686-025-01127-7","DOIUrl":"10.1007/s11686-025-01127-7","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to identify and analyze the role of Ferric reductase in<i>Blastocystis</i> sp. subtype 2 (ST2) and explore the relationship between the parasite and iron metabolism.</p><h3>Methods</h3><p>The location of <i>Ferric reductase in Blastocystis</i> sp. was determined using the indirect immunofluorescence assay (IFA). Transmission electron microscopy was employed to reveal the effect of iron ions on the cell membrane of<i> Blastocystis</i> sp.. For the first time, RNA interference technology was used to explore the relationship between<i> Ferric reductase</i> and iron ions.</p><h3>Results</h3><p><i>Ferric reductase</i> was distributed in the membrane and cytoplasm of the parasite. Iron reduces the thickness of the<i> Blastocystis</i> sp.'s cell membrane. After silencing the Ferric reductase gene, there was no significant difference in the morphology of the parasite strain compared with the control group. The expression level of the<i> Ferric reductase</i> gene does not play a decisive role in maintaining the morphology of the parasite, but the deletion of the<i> Ferric reductase</i> gene reduces the ability of the parasite to absorb iron ions.</p><h3>Conclusions</h3><p>This study fills the gap in the research field of iron metabolism in<i>Blastocystis</i> sp. among parasites, lays a foundation for the research on the gene function of<i> Blastocystis</i> sp., and provides new candidate factors for the development of<i> Blastocystis</i> sp. vaccines.</p></div>","PeriodicalId":6932,"journal":{"name":"Acta Parasitologica","volume":"70 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145021769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-09DOI: 10.1007/s11686-025-01128-6
Patindoilba Marcel Sawadogo, Jean Axel T. Kabore, Kiswendsida Thierry Guiguemde, Issiaka Soulama, Adama Zida
Introduction
The objective of the World Health Organization is to achieve the interruption of human African trypanosomiasis (HAT) transmission by 2030.
Methods
This review aims to update knowledge on HAT, through a synthesis on the epidemiology, diagnostic tools and drugs of HAT.
Results
From 1960 to 2024 approximately 132,063 cases of HAT have been reported across Africa. The majority of HAT patients live in the Democratic Republic of Congo (DRC). The Card Agglutination Test for Trypanosomiasis (CATT) remained for a long time the reference serology test for field screening. The immune trypanolysis test (ITL) test is an accurate serodiagnostic tool increasingly used for medical surveillance of sleeping sickness, but it is reserved for reference laboratories. Prototypes of TDRs such as SD BIOLINE HAT and, HAT Sero-K-SeT have been developed to respond to constraints posed with CATT and ITL, but lack specificity. Parasitological diagnosis techniques such as the mini-Anion Exchange by Centrifugation technique (mAECT) are used for mandatory confirmation of the disease before the initiation of treatment, but their sensitivity is low. To date, the active molecules against HAT are: pentamidine, suramin, melarsoprol, eflornithine and nifurtimox. The use of these molecules does not guarantee healing and generates many side effects. A new molecule has appeared in the therapeutic arsenal. This is fexinidazole, which was approved by the WHO in 2019 for the treatment of HAT due to T.b. gambiense. The WHO recommends the oral administration of this molecule in the first stage of the disease and in the second stage for non-severe cases. Since 2024, this molecule has also been approved by the WHO for the treatment of HAT due to T. b. rhodesiense.
Conclusion
All these difficulties raised raise questions about the need to develop new diagnostic tools that are more specific, more sensitive and better suited to field screening. They also call out the urgency of finding new drugs that are less toxic, easy to administer and more effective.
{"title":"Human African Trypanosomiasis (HAT): Epidemiology, Biological Diagnosis and Treatment: A Review","authors":"Patindoilba Marcel Sawadogo, Jean Axel T. Kabore, Kiswendsida Thierry Guiguemde, Issiaka Soulama, Adama Zida","doi":"10.1007/s11686-025-01128-6","DOIUrl":"10.1007/s11686-025-01128-6","url":null,"abstract":"<div><h3>Introduction</h3><p>The objective of the World Health Organization is to achieve the interruption of human African trypanosomiasis (HAT) transmission by 2030.</p><h3>Methods</h3><p>This review aims to update knowledge on HAT, through a synthesis on the epidemiology, diagnostic tools and drugs of HAT.</p><h3>Results</h3><p>From 1960 to 2024 approximately 132,063 cases of HAT have been reported across Africa. The majority of HAT patients live in the Democratic Republic of Congo (DRC). The Card Agglutination Test for Trypanosomiasis (CATT) remained for a long time the reference serology test for field screening. The immune trypanolysis test (ITL) test is an accurate serodiagnostic tool increasingly used for medical surveillance of sleeping sickness, but it is reserved for reference laboratories. Prototypes of TDRs such as SD BIOLINE HAT and, HAT Sero-K-SeT have been developed to respond to constraints posed with CATT and ITL, but lack specificity. Parasitological diagnosis techniques such as the mini-Anion Exchange by Centrifugation technique (mAECT) are used for mandatory confirmation of the disease before the initiation of treatment, but their sensitivity is low. To date, the active molecules against HAT are: pentamidine, suramin, melarsoprol, eflornithine and nifurtimox. The use of these molecules does not guarantee healing and generates many side effects. A new molecule has appeared in the therapeutic arsenal. This is fexinidazole, which was approved by the WHO in 2019 for the treatment of HAT due to <i>T.b. gambiense</i>. The WHO recommends the oral administration of this molecule in the first stage of the disease and in the second stage for non-severe cases. Since 2024, this molecule has also been approved by the WHO for the treatment of HAT due to <i>T. b. rhodesiense</i>. </p><h3>Conclusion</h3><p>All these difficulties raised raise questions about the need to develop new diagnostic tools that are more specific, more sensitive and better suited to field screening. They also call out the urgency of finding new drugs that are less toxic, easy to administer and more effective.</p></div>","PeriodicalId":6932,"journal":{"name":"Acta Parasitologica","volume":"70 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145021773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}